NEW YORK and BERLIN, February 12, 2025 – atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on revolutionizing mental health treatment, announced the pricing of its registered public offering. The offering involves 26,190,477 common shares at $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 shares. All shares will be sold by atai.

Before accounting for underwriting discounts, commissions, and other expenses, the gross proceeds are projected to be approximately $55 million. atai plans to use the net proceeds for general corporate purposes, including working capital and advancing its product candidates and programs through clinical development.

The offering is anticipated to close on February 14, 2025, contingent upon customary closing conditions.

Berenberg is acting as the sole underwriter for the offering.

The securities are offered under an effective shelf registration statement (filed with the SEC on July 1, 2022, and declared effective on July 11, 2022). This offering is solely through a prospectus supplement and accompanying prospectus, part of the effective shelf registration statement. A final prospectus supplement will be filed with the SEC and available on www.sec.gov. For copies, contact Berenberg Capital Markets LLC, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020; +1 (646) 949-9000; or .

This press release does not constitute an offer to sell or solicitation of an offer to buy securities where prohibited by law.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company dedicated to transforming mental health treatment. Founded in response to unmet needs and a lack of innovation in mental health care, atai focuses on developing novel, evidence-based therapeutics for depression, anxiety, and other mental health disorders. atai’s mission is to improve mental health globally.

Forward-looking Statements
This release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995). These include, but aren’t limited to, statements about offering completion, the option to purchase additional shares, the intended use of proceeds, and other statements about the offering. Actual results may differ materially due to various risks and uncertainties, as detailed in atai’s most recent 10-K and 10-Q filings with the SEC, and future filings. Forward-looking statements speak only as of today’s date, and atai disclaims any obligation to update them, except as required by law.

Contact Information
Investor Contact:

Media Contact:

“`